Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.44 |
| ▸ | MAPT | P10636 | 14/20 | 0.44 |
| ▸ | LMNA | P02545 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.44 |
| ▸ | HPGD | P15428 | 9/20 | 0.44 |
| ▸ | MEN1 | O00255 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | PKM | P14618 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985441 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL4982412 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL4006040 | 0.91 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL4055312 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL4002178 | 0.88 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL3999025 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL4007063 | 0.85 | MAPT (0.43) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL4006738 | 0.84 | DHODH (0.39) | ALDH1A1MAPTLMNASMN1; SMN2NPC1 | |
| SCHEMBL6510324 | 0.84 | DHODH (0.39) | ALDH1A1MAPTLMNASMN1; SMN2NPC1 | |
| SCHEMBL3998738 | 0.84 | DHODH (0.39) | ALDH1A1MAPTLMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538105-B2 | Anti-infective agents | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2009032177-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080193413-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| US-7378414-B2 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBOTT LABORATORIES (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050107364-A1 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBVIE INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005019191-A2 | 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C | ABBOTT LABORATORIES (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193413-A1 | Anti-Infective Agents | POLI, RPL5, POLRMT | ALDH1A1 2554/4885MAPT 3826/4885LMNA 3314/4885 |
| US-20050107364-A1 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | POLRMT, RNASE1, RNGTT | ALDH1A1 311/4885MAPT 4086/4885LMNA 2647/4885 |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | POLR2E, POLR2H, POLR2A | ALDH1A1 1531/4885MAPT 4141/4885LMNA 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.